CoChat

Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS

Open access

The DOI matches its Crossref record; 189 of the 190 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Polycystic ovary syndrome (PCOS) is characterized by elevated androgen production and subclinical changes in cardiovascular and metabolic risk markers. Total cholesterol, high-density lipoprotein (HDL) cholesterol, fasting glucose, and fasting insulin appear to increase specifically in PCOS compared with fertile women. PCOS also confers an increased risk of cardiometabolic disease in later life. Novel biomarkers such as serum’s cholesterol efflux capacity and blood-derived macrophage activation profile may assist in more accurately defining the cardiometabolic risk profile in these women. Aldosterone antagonists, androgen receptor antagonists, 5α-reductase inhibitors, and synthetic progestogens are used to reduce hyperandrogenism. Because increased insulin secretion enhances ovarian androgen production, short-term treatment with metformin and other hypoglycemic agents results in significant weight loss, favorable metabolic changes, and testosterone reduction. The naturally occurring inositols display insulin-sensitizing effects and may be also used in this context because of their safety profile. Combined oral contraceptives represent the drug of choice for correction of androgen-related symptoms. Overall, PCOS management remains focused on specific targets including assessment and treatment of cardiometabolic risk, according to disease phenotypes. While new options are adding to established therapeutic approaches, a sometimes difficult balance between efficacy and safety of available medications has to be found in individual women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21249554

Cites

189 of 190 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Alterations in macrophage functional phenotypes in PCOS. Macrophages are plastic cells that respond to pro- and anti-inflammatory stimuli to adjust to environmental changes and maintain homeostasis. Compared with healthy women, blood-derived macrophages from PCOS women are impaired in their response to cytokines, suggesting a reduced capacity to adjust to microenvironmental changes in different conditions. In addition, the serum from PCOS women is less effective in promoting cholesterol efflux from macrophage cell models with respect to that from healthy women. Cholesterol efflux is driven by serum HDL subfractions but also by other cellular and circulating factors. Impaired cholesterol efflux capacity is associated with an increased risk for atherothrombotic events. X: impairment observed in PCOS women vs. controls.
Figure 1 Alterations in macrophage functional phenotypes in PCOS. Macrophages are plastic cells that respond to pro- and anti-inflammatory stimuli to adjust to environmental changes and maintain homeostasis. Compared with healthy women, blood-derived macrophages from PCOS women are impaired in their response to cytokines, suggesting a reduced capacity to adjust to microenvironmental changes in different conditions. In addition, the serum from PCOS women is less effective in promoting cholesterol efflux from macrophage cell models with respect to that from healthy women. Cholesterol efflux is driven by serum HDL subfractions but also by other cellular and circulating factors. Impaired cholesterol efflux capacity is associated with an increased risk for atherothrombotic events. X: impairment observed in PCOS women vs. controls.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Show all 190 references

Research works printed but not linked: 1

  1. Scambia, 2019, The role of inositols in PCOS–opinion paper, Ital. J. Gynecol. Obstet., 31, 87

Cited by

See all 38

Metadata

Authors
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C.
Affiliations
  • University of Padua (IT)
  • AULSS 2 Marca Trevigiana (IT)
Corresponding author
Cignarella, Andrea
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-12-15
Volume
21
Issue
24
Pages
9554
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3112398518
Cited by
36
References
190
Citations by year
2026: 8 · 2025: 5 · 2024: 5 · 2023: 9 · 2022: 5 · 2021: 4
FWCI
0.67
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
polycystic ovary syndrome, cardiometabolic risk, hyperandrogenism, insulin resistance, metformin, myo-inositol, mineralocorticoid receptor antagonists, androgen receptor antagonists, 5-alpha reductase inhibitors, synthetic progestins, combined oral contraceptives, cholesterol efflux capacity, macrophage activation, cardiovascular risk, disease phenotypes
MeSH terms
Adult, Androgen Antagonists, Cardiovascular Diseases, Contraceptives, Oral, Disease Susceptibility, Female, Humans, Polycystic Ovary Syndrome, Risk Factors, Biomarkers, Outcome Assessment, Health Care, Risk Assessment, Chemoprevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. https://app.cochat.ai/papers/10.3390/ijms21249554
The paper
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020). Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21249554

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.